Sitemap | Kontakt | Impressum
Sprachen English Deutsch


Sie haben Fragen?

Gerne beraten wir Sie persönlich am Telefon:

+49 (0)431 69 10 747



Passwort vergessen?


Sie haben noch keine Artikel in Ihrem Warenkorb.

Alle Produktinformationen und -preise können jederzeit Änderungen unterliegen.


Die EU-Kommission hat gemäß EU-Verordnung Nr. 524/2013 eine interaktive Website (OS-Plattform) bereit gestellt, die der Beilegung außergerichtlicher Streitigkeiten aus Online-Rechtsgeschäften dient. Die OS-Plattform der EU-Kommission finden Sie unter diesem Link:
[<zurück] | [weiter>] |  [Letztes>>] |  62 Artikel in dieser Kategorie


Renal Cell Carcinoma

Molecular Features and Treatment Updates

Renal Cell Carcinoma

Februar 2017

Hardcover, 260 p., 56 ill.

Verlag: Springer

ISBN: 978-4-431-55530-8

171,19 EUR

inkl. 7 % MwSt.

Noch nicht erschienen, wir merken Ihre Bestellung vor

  • Provides a comprehensive review of diagnosis and treatments of renal cell carcinoma
  • Presents the most recent advances in molecular bases and targeted therapy for renal cell carcinoma
  • Contains important information about pharmacokinetics and pharmacodynamics in molecular- targeted agents of renal cell carcinoma

Renal Cell Carcinoma: Molecular Features and Treatment Updates provide a comprehensive review of diagnosis and treatments of renal cell carcinoma (RCC) for practitioners and researchers with an interest in this disease. A major aim of the book is to present the most important and most recent advances in molecular bases and targeted therapy for this neoplasm. The remarkable resistance to chemotherapy and radiotherapy and the minimum contribution of cancer genes that commonly mutate in other adult epithelial cancers have made RCC highly distinct from other types of solid neoplasms. In the past decade, however, treatment options for RCC have been expanding and moving quickly toward laboratory-based and molecular-targeted therapies. The United States Food and Drug Administration has approved four tyrosine-kinase inhibitors (TKIs), including sorafenib, sunitinib, pazopanib and axitinib and two mTOR inhibitors, including everolimus and temsirolimus. Advances in RCC therapy also have brought novel treatment options to other types of cancer, such as a TKI for hepatocellular carcinoma and gastrointestinal tumors, as well as mTOR inhibitors to progressive neuroendocrine tumors of pancreatic origin and breast cancer, suggesting that RCC is no longer an "orphan disease" in the field of molecular oncology. Additional topics covered in the book include pharmacokinetics and pharmacodynamics in molecular-targeted agents and the putative mechanism of resistance to anti-angiogenic agents, such as intratumoral heterogeneity or cancer stem cell population. This volume provides the latest and most useful information for all readers who are eagerly devoted to curing renal cell carcinoma.